UNI-BIO GROUP (00690) announced its interim results, with profit decreasing by 59.0% year-on-year to approximately HK$31.2 million.

UNI-BIO GROUP (00690) announced its interim results for 2026, with revenue of approximately HKD 274 million, a year-on-year decrease of 11.75%; profit decreased by 59.0% year-on-year to approximately HKD 31.2 million, with earnings per share of about HKD 0.52. The announcement stated that the sales volume of major products continued to grow during the period, particularly for BoGuTai and JinYinPeptide. However, revenue was impacted by one-time pricing adjustments during the period, mainly including the repricing after the successful renewal of the centralized volume-based procurement for PiNaPu and the strategic expansion of hospital access and prescription base for JinYinPeptide through participation in the Guangdong Alliance Drug Centralized Procurement Project, as well as the impact of the increase in the value-added tax rate on biological products from 3% to 13% on net selling prices. The decrease in profit mainly reflects the short-term profit pressure during the group's strategic transformation period, which includes the decline in gross profit absolute value due to pricing adjustments for several core products and the price impact related to value-added tax, as well as the continuous investment in commercialization, new product launches, pipeline development, and international expansion.